1.Dendritic Cell-Based Cancer Immunotherapy.
Journal of the Korean Pediatric Society 2003;46(10):947-951
No abstract available.
Immunotherapy*
2.Safety of ultrarush immunotherapy.
Allergy, Asthma & Respiratory Disease 2017;5(6):305-306
No abstract available.
Immunotherapy*
3.The Evaluation for the Immunotherapy to Bronchial Asthmatics.
Journal of the Korean Pediatric Society 1987;30(3):247-252
No abstract available.
Immunotherapy*
4.Immunotherapy with "mesima EX" in the treatments of digestive cancers.
Bong Hwa LEE ; Kee Chun HONG ; Yong Kwan CHO ; Doo Sun LEE ; Jung Hyun YANG ; Kyung Woo CHOI ; Chong Heung KIM ; Ze Hong WOO ; Chan Young LEE ; Heung Gil PARK
Journal of the Korean Cancer Association 1991;23(3):571-577
No abstract available.
Immunotherapy*
5.Allergic Diseases and Immunotherapy.
Journal of the Korean Pediatric Society 1987;30(11):1189-1195
No abstract available.
Immunotherapy*
6.Intralymphatic Immunotherapy Alleviates Allergic Symptoms During Allergen Exposure in Daily Life.
Sang Pyo LEE ; Joo Hyun JUNG ; Sang Min LEE ; Eugene JOE ; Il Gyu KANG ; Seon Tae KIM ; Min Woo LEE ; So Hyun PARK ; Seung Joon CHOI
Allergy, Asthma & Immunology Research 2018;10(2):180-181
No abstract available.
Immunotherapy*
7.Natural killer cell-based immunotherapy for treating cancer: will it be promising?.
Duck CHO ; Sang Ki KIM ; William E CARSON
Korean Journal of Hematology 2011;46(1):3-5
No abstract available.
Immunotherapy
8.Research advances in sporadic late-onset nemaline myopathy
Journal of Apoplexy and Nervous Diseases 2025;42(5):409-413
Sporadic late-onset nemaline myopathy (SLONM) is a rare, acquired, and treatable myopathy with a subacute or chronic progressive clinical course, characterized by asymmetric muscle atrophy and weakness in the axial and limb muscles, with or without involvement of respiratory and cardiac muscles. The only definitive diagnostic method at present is the identification of rods accumulation in muscle fibers by muscle biopsy pathology. This article provides a review of the clinical manifestations, diagnostic evaluations, muscle pathology, and advances in the treatment of SLONM.
Immunotherapy
9.Editorial: The past,present,and future of autoimmune encephalitis
Journal of Apoplexy and Nervous Diseases 2025;42(6):483-486
Autoimmune encephalitis(AE)is a type of brain inflammation caused by the immune system mistaking autoantigens expressed in the central nervous system for foreign antigens,thereby resulting in abnormal immune response that affects brain parenchyma(cortex or deep gray matter and white matter)and may involve the meninges and spinal cord. This disease is not an infectious inflammatory disease caused by pathogen invasion and is fundamentally different from purulent encephalitis and viral encephalitis,and it can occur in different populations such as children,adolescents,and adults. A recent epidemiological study from the United States shows that there might be a higher prevalence rate of AE,and the prevalence rate of AE was 13.7/100 000 in this population-based study,with no significant difference from the prevalence rate of infectious encephalitis. Since the discovery of anti-N-methyl-D-aspartate(NMDA)receptor antibodies,many patients who experience mental symptoms with rapid progression,abnormal behavior,seizures,or unexplained coma have been diagnosed with AE. The onset of symptoms is usually unclear,which might be similar to mental illness,but then the disease often progresses rapidly and causes damage to brain parenchyma and even loss of consciousness and coma,which usually requires intensive care. Therefore,a comprehensive and systematic understanding of AE is of great significance for clinicians to achieve early identification,diagnosis,and treatment and help patients obtain a good prognosis. This article aims to provide a comprehensive overview of existing research findings of AE in terms of its past,present,and future development and from cognitive limitations to the leap towards precision treatment,in order to provide assistance for diagnosis and treatment among clinicians.
Immunotherapy
10.A Case of Cutaneous Metastatic Melanoma Treated with Topical Diphencyprone (DPCP).
Yun Seon CHOE ; Jung Yoon OHN ; Mira CHOI ; Kwang Hyun CHO
Korean Journal of Dermatology 2016;54(5):403-404
No abstract available.
Immunotherapy
;
Melanoma*